乌鸦传媒視頻

This is an abstract. The full journal study is available to read via the link in the source information below.

Background

Transmission-blocking interventions can play an important role in combating malaria worldwide. Recently, a highly potent Plasmodium falciparum transmission-blocking monoclonal antibody (TB31F) was demonstrated to be safe and efficacious in malaria-naïve volunteers. Here we predict the potential public health impact of large-scale implementation of TB31F alongside existing interventions.

Methods

We developed a pharmaco-epidemiological model, tailored to 2 settings of differing transmission intensity with already established insecticide-treated nets and seasonal malaria chemoprevention interventions.

Results

Community-wide annual administration (at 80% coverage) of TB31F over a 3-year period was predicted to reduce clinical incidence by 54% (381 cases averted per 1000 people per year) in a high-transmission seasonal setting, and 74% (157 cases averted per 1000 people per year) in a low-transmission seasonal setting. Targeting school-age children gave the largest reduction in terms of cases averted per dose. An annual administration of the transmission-blocking monoclonal antibody TB31F may be an effective intervention against malaria in seasonal malaria settings.

Conclusion

We have shown that TB31F may be an effective intervention against malaria in settings with a well-defined malaria season.

Read an interview about the study here.

The full text of this study can be accessed via the source information below.